Call for Abstract

19th World Congress on Advances in Pharmaceutical Sciences, will be organized around the theme “Potential Challenges and Strategies to Tackle Emerging Pharma Innovations”

Pharm Sci 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Pharm Sci 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

The pharmaceutical sciences combine a broad range of scientific disciplines that are critical to the discovery and development of new drugs and therapies. Pharmaceutical Sciences is a dynamic and interdisciplinary field that aims to integrate fundamental principles of physical and organic chemistry, engineering, biochemistry, and biology to understand how to optimize delivery of drugs to the body and translate this integrated understanding into new and improved therapies against human disease. At the many of institutes internationally recognized faculty contribute to the field through inquiry into the underlying mechanisms of drug interactions with the human body and development of advanced synthetic or biologically-derived materials that can modulate these interactions in pursuit of better and safer therapies and drug products.

  • Track 1-1Advancements in pharmaceutical technology
  • Track 1-2Pharmacological vitality of drugs
  • Track 1-3Pharmacotherapy
  • Track 1-4Neuropharmacology
  • Track 1-5Pharmacokinetics and Pharmacodynamics
  • Track 1-6Molecular drug targets and delivery
  • Track 1-7Pharmacoepidemiology and drug safety
  • Track 1-8Pharmacoeconomics
  • Track 1-9Machine learning in drug discovery

Drug particles in the nanometer size range have unique characteristics that can lead to enhanced performance in a variety of dosage forms. Formulated correctly, particles in this size range are resistant to settling and can have higher saturation solubility, rapid dissolution, and enhanced adhesion to biological surfaces, thereby providing a rapid onset of therapeutic action and improved bioavailability. Scientists at Cirrus Pharmaceuticals, Inc. use nanotechnology to approach classical and novel drug delivery applications. We provide services for producing, formulating, and characterizing nanoparticles for a wide array of applications including, but not limited to, oral, pulmonary and parenteral delivery. Pharmaceutical Nanotechnology deals with emerging new technologies for developing customized solutions for drug delivery systems. 

  • Track 2-1Characterization of Pharmaceutical Nanotools
  • Track 2-2Engineering of Pharmaceutical Nanosystems
  • Track 2-3Applications of Pharmaceutical Nanotools
  • Track 2-4Future Prospects of Pharmaceutical Nanotechnology
  • Track 2-5Challenges to Pharmaceutical Nanotechnology

The last few years have been a positive period overall for both the pharmaceutical and biotechnology industries. Most importantly, there has been a renaissance with regard to the increase in the number of new drugs approved and under development for the two segments of the business.

Many of these innovations are driven by new research methods and the growth of new therapeutic options, such as immune-related oncology drugs, personalized medicine, stem cells, and biologics. We are also witnessing the development of a greater number of drugs that cure diseases rather than just extend life.

  • Track 3-1Pharma’s Changing Landscape
  • Track 3-2Boom in Biotech
  • Track 3-3Pharma: What will the future bring?
  • Track 3-4Biotech: What will the future bring?

The most fundamental goal in drug design is to predict whether a given molecule will bind to a target and if so how strongly. Molecular mechanics or molecular dynamics are most often used to predict the conformation of the small molecule and to model conformational changes in the biological target that may occur when the small molecule binds to it. The therapeutic response of a drug depends upon the interaction of drug molecules with a cell on cell membrane related biological events at receptor sites in a concentration-dependent manner. Selective and effective localization of the pharmacologically-active moiety at pre-identified target(s) in therapeutic concentration, while restricting its access to non-target(s) normal cellular linings, thus minimizing toxic effects and maximizing the therapeutic index accounts from effective and efficient drug delivery

  • Track 4-1Factors influencing Drug Targeting
  • Track 4-2Advances in Drug Targeting components
  • Track 4-3Recent Approaches to Drug Targeting
  • Track 4-4Rational Drug Design
  • Track 4-5Computer Aided Drug Design
  • Track 4-6Drug Design Theory
  • Track 4-7Role of Computers in Drug Design: Their Success and Failure

Biopharmaceutical Science contains a study of the drug discovery and their development, and along with their properties, both physical and chemical. It also deals with the biological effects of the drugs like onset and duration of action along with their intensity in the body. Biopharmaceutics help in calculating the bioavailability and therapeutic activity of the drugs in the body

  • Track 5-1Biosimilars and Biologic Drugs
  • Track 5-2Formulation Studies for Biotherapeutics
  • Track 5-3Drug Dissolution of Biopharmaceutical Products
  • Track 5-4Drug Dissolution of Biopharmaceutical Products
  • Track 5-5Drug Dissolution of Biopharmaceutical Products
  • Track 5-6BA/BE on Biopharmaceutical Product
  • Track 5-7Biopharmaceutical Companies & Market analysis

The branch of genetics concerned with determining the likely response of an individual to therapeutic drugs. Its name reflects it’s combining of pharmacology and genomics. It deals with the influences such as acquired and inherited genetic variation on drug response in patients by correlating gene expression or single-nucleotide with pharmacokinetics and pharmacodynamics (, distribution, metabolism, and elimination), as well as drug receptor target effects.

  • Track 6-1Precision Medicine in Cancer
  • Track 6-2Emerging Areas in Pharmacogenomics
  • Track 6-3Epigenetics
  • Track 6-4Genome enabled biochemistry
  • Track 6-5Pharmacogenomics in Clinical Therapeutics
  • Track 6-6Human genomics
  • Track 6-7Gene therapy

Preformulation begins when a newly produced drug shows the sufficient pharmacologic promise in the animal models to warrant evaluation in the man. And these studies mainly focus on the physicochemical properties of the new compound that could affect drug performance such as action and also in drug development.

  • Track 7-1Biopharmaceutics and Biotherapeutics
  • Track 7-2Drug designing
  • Track 7-3Drug Selection
  • Track 7-4Drug-excipient compatibility
  • Track 7-5PK-PD Modeling of Drugs
  • Track 7-6Accelerated Stability Studies
  • Track 7-7Solubility Hindrance
  • Track 7-8Multiple dosing
  • Track 7-9Drug-dose safety

For developing a new medicine it will take nearly 10-15 years and on average and costs an average of $2.6 billion. In discovery, the procedure comprises the initial stages of research, which are intended to recognize an investigational drug and perform primary tests in the lab. This first stage of the process takes three to six years. By the end, investigators hope to identify a capable drug aspirant to further study in the lab and in animal models, and then in people. These developments offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used along with diagnostics, clinical trial protocols must be improved and increased.


  • Track 8-1Analytical strategies for pharmaceutical products
  • Track 8-2Analytical strategies for pharmaceutical products
  • Track 8-3Recent trends in Drug Discovery and Development
  • Track 8-4Pharmacoeconomics and pharma market research
  • Track 8-5Drug Prices and Consumer Value in R&D
  • Track 8-6Stability of drugs

Good Manufacturing Practice is the part of quality management which ensures that products are consistently produced and controlled according to the quality standards appropriate to their intended use and as required by the marketing authorization, clinical trial authorization or product specification. Good Manufacturing practices conference aims at both production and Quality Control. Current Good Manufacturing Practices (cGMP) is aimed primarily at managing and minimizing the risks inherent in pharmaceutical manufacture to ensure the quality, safety, and efficacy of products. FDA regulates the quality of pharmaceuticals very carefully. Current Trends in the FDA is the main regulatory standard for ensuring pharmaceutical quality.


  • Track 9-1Facts about current good manufacturing practices (cGMPs)
  • Track 9-2Good automated manufacturing practice (GAMP
  • Track 9-3FDA good manufacturing practices
  • Track 9-4GMP/GCP interface & GMP audits
  • Track 9-5GMPs for OTC and cosmetic products – global requirements
  • Track 9-6GMPs for medical devices
  • Track 9-7GMPs for medical devices
  • Track 9-8GMP requirements & standards

International Organization for Standardization (ISO) 9000 requirements do not have the same status as “the law” in the U.S. as do requirements listed in the Code of Federal Regulations (CFR). Because 21 CFR 210 and 211 have legal status, the U.S. Justice Department has extensive powers to ensure compliance. For example, product in the marketplace can be seized, fines can be levied, and personal liability can be assigned. So, management must understand that auditing must be taken seriously, and the requirements listed are just that – requirements. While audits are commonplace in the pharmaceutical industry, the preparedness for those events varies. The companies that develop a risk-based approach to audits are able to remain competitive while meeting quality and government compliance standards on a regular basis. Conversely, the companies that have not implemented strong processes are putting themselves at risk for non-compliance. According to the Federal Food, Drug and Cosmetic Act, “Registered domestic drug establishments shall be inspected by the FDA at least once every two years.” Under some conditions the inspections may be even more frequent, As regulations become more stringent, regulatory authorities are likely to step up audits which are even more reason for companies to be prepared.


  • Track 10-1The Audit as a Quality Control Mechanism
  • Track 10-2Adequate supervisory control
  • Track 10-3Quality control plans
  • Track 10-4Proper administration of a benefit plan

In the fields of prescription, biotechnology, and pharmacology, sedate revelation is the procedure by which new candidate medications are found. Generally, medications were found through recognizing the dynamic fixing from customary cures or by fortunate revelation. Later compound libraries of manufactured little particles, characteristic items or extracts were screened in place cells or entire life forms to recognize substances that have an alluring remedial impact in a procedure known as traditional pharmacology. Since the sequencing of the human genome which permitted fast cloning and amalgamation of vast amounts of cleaned proteins, it has ended up basic practice to utilize high throughput screening of expansive mixes libraries against confined organic targets which are speculated to be illness altering in a procedure known as a turn around pharmacology. Hits from these screens are then tried in cells and after that in creatures for adequacy.


  • Track 11-1Case Studies at Different Trial Phases
  • Track 11-2Pre -Clinical Studies
  • Track 11-3Regulatory Update
  • Track 11-4Clinical Design
  • Track 11-5Upcoming Challenges in Clinical Trails

This track includes  Pharmaceutical Formulation which is the process in which different chemical substances i.e., active chemical substances will combine together to produce a medical compound i.e., medical drug. This process involves the production of drug which characterized by two things: Stability of the product, second Acceptability to the patient. Formulation studies focus on factors like particle size, polymorphism, pH and solubility, in order to check whether these factors will affect the bioavailability of the drug or not. Pharmaceutical Formulations include Ophthalmic Formulation, Paediatric Formulation Development, Topical Formulation, and Medication Formulation.


  • Track 12-1Pharmaceutical Excipients
  • Track 12-2Pharmaceutical Product Development
  • Track 12-3Types of Drug Formulation
  • Track 12-4Ophthalmic Formulation
  • Track 12-5Pediatric Formulation Development
  • Track 12-6Medication Formulation
  • Track 12-7Topical Formulations

The API market in the US is as expected to grow at a CAGR of 7% over the period 2014-2019. The market research and analysis estimates that in terms of geographic regions, the Americas will be the major revenue contributor to the active pharmaceutical ingredients market throughout the next four years. The increasing demand for generic drugs from countries such as the US, the growth in aging population, and the presence of an organized R&D structure for drug development are some of the major factors that will drive the growth of the market in this region.  The key vendors in this sector are Abbott Laboratories, Aurobindo Pharma, Mylan, and Teva Pharmaceutical Industries.


  • Track 13-1European API market
  • Track 13-2European API market
  • Track 13-3API outsourcings
  • Track 13-4US API market
  • Track 13-5Asian API market
  • Track 13-6Antibody Drug Conjugate (ADCs)
  • Track 13-7Highly Potent Active Pharmaceutical Ingredients (HPAPIs)
  • Track 13-8Biological API market

The term is Pharmaceutical Biotechnology which is the branch of science that deals with all the technologies required for manufacturing, producing and registration of biological drugs. Pharmaceutical Biotechnology is an increasingly essential area of science and technology. The Pharmaceutical Biotechnology has largely spread area, ranging from many ethical issues to changes in healthcare practices and a significant contribution to the development of the national economy. Biotech drug makers mainly use those microorganisms or highly complex proteins from genetically-modified living cells as components in medications to treat various diseases and conditions, from cancer to rheumatoid arthritis to multiple sclerosis.


  • Track 14-1Microarray Technology
  • Track 14-2Industrial Biotechnology
  • Track 14-3Bioformulations
  • Track 14-4Vaccines and Antibiotics
  • Track 14-5Nucleic Acid Products
  • Track 14-6Biologically inspired Pharmaceutics

This term Nano pharmaceutical gives an ability to identify the diseases at very earlier stages and the diagnostic applications can build upon the conventional procedures using nanoparticles. Nanopharmaceuticals is considered an emerging field where the sizes of the drug molecule or a therapeutic delivery system work at a  Nanoscale. In the pharmaceutical industry, a never-ending issue is a difficulty of delivering the appropriate dose of a particular active medication to the specific diseased site. Nanopharmaceuticals have enormous potential in addressing this failure of traditional therapeutics which offers site-specific targeting of active agents.


  • Track 15-1Nanomedicine
  • Track 15-2Biomedical Nanotechnology
  • Track 15-3Nanotechnology and Nanomedicine
  • Track 15-4Nano Drug Delivery
  • Track 15-5Nano Liposomes
  • Track 15-6Nano Pharmaceuticals
  • Track 15-7Applied Nanotechnology